SOX4 Serves an Oncogenic Role in the Tumourigenesis of Human Breast Adenocarcinoma by Promoting Cell Proliferation, Migration and Inhibiting Apoptosis

Author(s): Junhe Zhang*, Shujie Chai, Xinyu Ruan

Journal Name: Recent Patents on Anti-Cancer Drug Discovery

Volume 15 , Issue 1 , 2020

Become EABM
Become Reviewer

Abstract:

Background: Breast cancer is among the most common malignant cancers worldwide, and breast adenocarcinoma in glandular tissue cells has excessive metastasis and invasion capability. However, little is known on the molecular process by which this disease develops and progresses.

Objective: In this study, we explored the effects of sex-determining region Y-box 4 (SOX4) protein on proliferation, migration, apoptosis and tumourigenesis of breast adenocarcinoma and its possible mechanisms.

Methods: The SOX4 overexpression or knockdown Michigan Cancer Foundation-7 (MCF-7) cell lines were established. Among the SOX4 overexpression or MCF-7 knockdown cell lines, proliferation, migration ability and apoptosis rate were detected. The expression levels of apoptosis-related proteins (Bax and Cleaved caspase-3) were analysed using Western blot. The effect of SOX4 on tumourigenesis was analysed using the clone formation assay in vitro and tumour xenograft experiment in nude mice.

Results: Compared with the overexpression of control cells, proliferation and migration ability of SOX4 overexpression cells significantly increased, the apoptosis rate significantly decreased in addition to the expression levels of Bax and Cleaved caspase-3 (P < 0.05). Compared with the knockdown of control cells, proliferation and migration ability of SOX4 knockdown cells significantly decreased, and the apoptosis rate and expression levels of Bax and Cleaved caspase-3 significantly increased (P < 0.05). Clone formation and tumour growth abilities of SOX4 overexpression cells were significantly higher than those of the control cells (P < 0.05), whereas SOX4 knockdown cells had the opposite effect.

Conclusion: SOX4 plays an oncogenic role in breast adenocarcinoma tumourigenesis by promoting cell proliferation, migration and inhibiting apoptosis. It can be used as a potential molecular target for breast cancer gene therapy.

Keywords: Apoptosis, breast adenocarcinoma, migration, proliferation, SOX4, tumorigenesis.

[1]
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65(2): 87-108.
[http://dx.doi.org/10.3322/caac.21262] [PMID: 25651787]
[2]
Zhao S, Dong H, Qin J, et al. Breast cancer mortality in Chinese women: does migrant status play a role? Ann Epidemiol 2019; 40: 28-34.e2.
[http://dx.doi.org/10.1016/j.annepidem.2019.10.006] [PMID: 31753691]
[3]
Bala A, Panditharadyula SS. Role of nuclear factor erythroid 2-related factor 2 (NRF-2) mediated antioxidant response on the synergistic antitumor effect of L-arginine and 5-Fluro Uracil (5FU) in breast adenocarcinoma. Curr Pharm Des 2019; 25(14): 1643-52.
[http://dx.doi.org/10.2174/1381612825666190705205155] [PMID: 31298161]
[4]
Osborne C, Wilson P, Tripathy D. Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. Oncologist 2004; 9(4): 361-77.
[http://dx.doi.org/10.1634/theoncologist.9-4-361] [PMID: 15266090]
[5]
Sharma GN, Dave R, Sanadya J, Sharma P, Sharma KK. Various types and management of breast cancer: an overview. J Adv Pharm Technol Res 2010; 1(2): 109-26.
[PMID: 22247839]
[6]
DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin 2016; 66(1): 31-42.
[http://dx.doi.org/10.3322/caac.21320] [PMID: 26513636]
[7]
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66(2): 115-32.
[http://dx.doi.org/10.3322/caac.21338] [PMID: 26808342]
[8]
Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends - - an update. Cancer Epidemiol Biomarkers Prev 2016; 25(1): 16-27.
[http://dx.doi.org/10.1158/1055-9965.EPI-15-0578] [PMID: 26667886]
[9]
Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China. Lancet Oncol 2014; 15(7): e279-89.
[http://dx.doi.org/10.1016/S1470-2045(13)70567-9] [PMID: 24872111]
[10]
Piggin CL, Roden DL, Law AMK, et al. ELF5 modulates the estrogen receptor cistrome in breast cancer. PLoS Genet 2020; 16(1) e1008531
[http://dx.doi.org/10.1371/journal.pgen.1008531] [PMID: 31895944]
[11]
Jiang ST, Wang HQ, Yang TC, et al. Expression of stanniocalcin 2 in breast cancer and its clinical significance. Curr Med Sci 2019; 39(6): 978-83.
[http://dx.doi.org/10.1007/s11596-019-2131-2] [PMID: 31845230]
[12]
Saberi Ansar E, Eslahchii C, Rahimi M, et al. Significant random signatures reveals new biomarker for breast cancer. BMC Med Genomics 2019; 12(1): 160.
[http://dx.doi.org/10.1186/s12920-019-0609-1] [PMID: 31703592]
[13]
Liu XL, Brown M, Li W, Xiao TF. Biomarkers predictive of endocrine resistance in breast cancer US2019390280. (2019).
[14]
Peterson AC, Uppal H. Method for predicting response to breast cancer therapeutic agents and method of treatment of breast cancer ZA201703904. (2019).
[15]
Schepers GE, Teasdale RD, Koopman P. Twenty pairs of sox: extent, homology, and nomenclature of the mouse and human sox transcription factor gene families. Dev Cell 2002; 3(2): 167-70.
[http://dx.doi.org/10.1016/S1534-5807(02)00223-X] [PMID: 12194848]
[16]
Nissen-Meyer LS, Jemtland R, Gautvik VT, et al. Osteopenia, decreased bone formation and impaired osteoblast development in Sox4 heterozygous mice. J Cell Sci 2007; 120(Pt 16): 2785-95.
[http://dx.doi.org/10.1242/jcs.003855] [PMID: 17652162]
[17]
Sun B, Mallampati S, Gong Y, Wang D, Lefebvre V, Sun X. Sox4 is required for the survival of pro-B cells. J Immunol 2013; 190(5): 2080-9.
[http://dx.doi.org/10.4049/jimmunol.1202736] [PMID: 23345330]
[18]
Kuwahara M, Yamashita M, Shinoda K, et al. The transcription factor Sox4 is a downstream target of signaling by the cytokine TGF-β and suppresses T(H)2 differentiation. Nat Immunol 2012; 13(8): 778-86.
[http://dx.doi.org/10.1038/ni.2362] [PMID: 22751141]
[19]
Wang B, Li Y, Tan F, Xiao Z. Increased expression of SOX4 is associated with colorectal cancer progression. Tumour Biol 2016; 37(7): 9131-7.
[http://dx.doi.org/10.1007/s13277-015-4756-5] [PMID: 26768610]
[20]
Bao ZQ, Zhang CC, Xiao YZ, Zhou JS, Tao YS, Chai DM. Over-expression of Sox4 and β-catenin is associated with a less favorable prognosis of osteosarcoma. J Huazhong Univ Sci Technolog Med Sci 2016; 36(2): 193-9.
[http://dx.doi.org/10.1007/s11596-016-1565-z] [PMID: 27072961]
[21]
Bilir B, Osunkoya AO, Wiles WG, et al. SOX4 is essential for prostate tumorigenesis initiated by PTEN ablation. Cancer Res 2016; 76(5): 1112-21.
[http://dx.doi.org/10.1158/0008-5472.CAN-15-1868] [PMID: 26701805]
[22]
Mehta GA, Parker JS, Silva GO, Hoadley KA, Perou CM, Gatza ML. Amplification of SOX4 promotes PI3K/Akt signaling in human breast cancer. Breast Cancer Res Treat 2017; 162(3): 439-50.
[http://dx.doi.org/10.1007/s10549-017-4139-2] [PMID: 28176176]
[23]
Vanaja D, Young CY. Methods and compositions for diagnosis, staging and prognosis of prostate cancer WO2005007830. (2005).
[24]
Song GD, Sun Y, Shen H, Li W. SOX4 overexpression is a novel biomarker of malignant status and poor prognosis in breast cancer patients. Tumour Biol 2015; 36(6): 4167-73.
[http://dx.doi.org/10.1007/s13277-015-3051-9] [PMID: 25592378]
[25]
Fan JD, Jiang LX, Zhou ZW. Recombinant lentiviral vector preparation US2015056696. (2015).
[26]
Zhang JH, Du AL, Wang L, Wang XY, Gao JH, Wang TY. Episomal lentiviral vector-mediated miR-145 overexpression inhibits proliferation and induces apoptosis of human esophageal carcinomas cells. Recent Patents Anticancer Drug Discov 2016; 11(4): 453-60.
[http://dx.doi.org/10.2174/1574892811666160822161157] [PMID: 27549139]
[27]
Zhang JH, Xia HB. Lentiviral-mediated overexpression of microRNA-141 promotes cell proliferation and inhibits apoptosis in human esophageal squamous cell carcinoma. Recent Patents Anticancer Drug Discov 2019; 14(2): 170-6.
[http://dx.doi.org/10.2174/1574892814666181231142136] [PMID: 30599110]
[28]
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25(4): 402-8.
[http://dx.doi.org/10.1006/meth.2001.1262] [PMID: 11846609]
[29]
Moran JD, Kim HH, Li Z, Moreno CS. SOX4 regulates invasion of bladder cancer cells via repression of WNT5a. Int J Oncol 2019; 55(2): 359-70.
[http://dx.doi.org/10.3892/ijo.2019.4832] [PMID: 31268162]
[30]
Lourenço AR, Coffer PJ. SOX4: joining the master regulators of epithelial-to-mesenchymal transition? Trends Cancer 2017; 3(8): 571-82.
[http://dx.doi.org/10.1016/j.trecan.2017.06.002] [PMID: 28780934]
[31]
Potzner MR, Tsarovina K, Binder E, et al. Sequential requirement of Sox4 and Sox11 during development of the sympathetic nervous system. Development 2010; 137(5): 775-84.
[http://dx.doi.org/10.1242/dev.042101] [PMID: 20147379]
[32]
Schilham MW, Oosterwegel MA, Moerer P, et al. Defects in cardiac outflow tract formation and pro-B-lymphocyte expansion in mice lacking Sox-4. Nature 1996; 380(6576): 711-4.
[http://dx.doi.org/10.1038/380711a0] [PMID: 8614465]
[33]
Shi S, Cao X, Gu M, You B, Shan Y, You Y. Upregulated expression of SOX4 is associated with tumor growth and metastasis in nasopharyngeal carcinoma. Dis Markers 2015; 2015 658141
[http://dx.doi.org/10.1155/2015/658141] [PMID: 26578818]
[34]
Zhang J, Jiang H, Shao J, et al. SOX4 inhibits GBM cell growth and induces G0/G1 cell cycle arrest through Akt-p53 axis. BMC Neurol 2014; 14: 207.
[http://dx.doi.org/10.1186/s12883-014-0207-y] [PMID: 25366337]
[35]
Wang D, Hao T, Pan Y, Qian X, Zhou D. Increased expression of SOX4 is a biomarker for malignant status and poor prognosis in patients with non-small cell lung cancer. Mol Cell Biochem 2015; 402(1-2): 75-82.
[http://dx.doi.org/10.1007/s11010-014-2315-9] [PMID: 25567207]
[36]
Cai H, Ni A, Li W, Li J. Inhibition of melanoma cell proliferation by targeting Wnt/β-catenin pathway through Sox4 RNA interference. J Huazhong Univ Sci Technolog Med Sci 2011; 31(4): 565.
[http://dx.doi.org/10.1007/s11596-011-0491-3] [PMID: 21823023]
[37]
Sun R, Jiang B, Qi H, et al. SOX4 contributes to the progression of cervical cancer and the resistance to the chemotherapeutic drug through ABCG2. Cell Death Dis 2015; 6 e1990
[http://dx.doi.org/10.1038/cddis.2015.290] [PMID: 26583330]
[38]
Dong H, Hu J, Wang L, et al. SOX4 is activated by C-MYC in prostate cancer. Med Oncol 2019; 36(11): 92.
[http://dx.doi.org/10.1007/s12032-019-1317-6] [PMID: 31560094]
[39]
Chen J, Ju HL, Yuan XY, Wang TJ, Lai BQ. SOX4 is a potential prognostic factor in human cancers: a systematic review and meta-analysis. Clin Transl Oncol 2016; 18(1): 65-72.
[http://dx.doi.org/10.1007/s12094-015-1337-4] [PMID: 26250764]
[40]
Vervoort SJ, van Boxtel R, Coffer PJ. The role of SRY-related HMG box transcription factor 4 (SOX4) in tumorigenesis and metastasis: friend or foe? Oncogene 2013; 32(29): 3397-409.
[http://dx.doi.org/10.1038/onc.2012.506] [PMID: 23246969]
[41]
Aaboe M, Birkenkamp-Demtroder K, Wiuf C, et al. SOX4 expression in bladder carcinoma: clinical aspects and in vitro functional characterization. Cancer Res 2006; 66(7): 3434-42.
[http://dx.doi.org/10.1158/0008-5472.CAN-05-3456] [PMID: 16585165]
[42]
Lai YH, Cheng J, Cheng D, et al. SOX4 interacts with plakoglobin in a Wnt3a-dependent manner in prostate cancer cells. BMC Cell Biol 2011; 12: 50.
[http://dx.doi.org/10.1186/1471-2121-12-50] [PMID: 22098624]
[43]
Han NN, Zhou Q, Huang Q, Liu KJ. Carnosic acid cooperates with tamoxifen to induce apoptosis associated with Caspase-3 activation in breast cancer cells in vitro and in vivo. Biomed Pharmacother 2017; 89: 827-37.
[http://dx.doi.org/10.1016/j.biopha.2017.01.084] [PMID: 28282784]
[44]
Sugiura R, Takasaki T, Sato R, Muraoka O, Tanabe G. Apoptosis inducers and therapeutic agents for cancer JP2019085381. (2019).
[45]
Xiang ZM, Qin YP, Ma HT, et al. Oyster cell apoptosis gene caspase 3 gene and application thereof in preparation of pathological detection and diagnosis reagent CN108610406. (2018).
[46]
Kobayashi T, Masumoto J, Tada T, Nomiyama T, Hongo K, Nakayama J. Prognostic significance of the immunohistochemical staining of cleaved caspase-3, an activated form of caspase-3, in gliomas. Clin Cancer Res 2007; 13(13): 3868-74.
[http://dx.doi.org/10.1158/1078-0432.CCR-06-2730] [PMID: 17606719]
[47]
Ponder KG, Boise LH. The prodomain of caspase-3 regulates its own removal and caspase activation. Cell Death Discov 2019; 5: 56.
[http://dx.doi.org/10.1038/s41420-019-0142-1] [PMID: 30701088]
[48]
Mignard V, Lalier L, Paris F, Vallette FM. Bioactive lipids and the control of Bax pro-apoptotic activity. Cell Death Dis 2014; 5 e1266
[http://dx.doi.org/10.1038/cddis.2014.226] [PMID: 24874738]
[49]
Walensky LD, Gavathiotis E. Pyrazol-3-ones that activate proapoptotic Bax US2019315730 (2019).
[50]
Walensky LD, Pritz J, Wachter F. Small molecule sensitization of BAX activation for induction of cell death AU2018236233. (2019).


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 15
ISSUE: 1
Year: 2020
Page: [49 - 58]
Pages: 10
DOI: 10.2174/1574892815666200212112119
Price: $65

Article Metrics

PDF: 16
HTML: 2
EPUB: 1
PRC: 1